{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-034506","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.611954+00:00","generated_at":"2026-05-15T09:04:15.936865+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Journey Medical FY2025 revenue $61.9M (+10% YoY); net loss narrows to $11.4M","bullets":["Emrosi launch contributed $14.7M net revenue; ~53,000 prescriptions filled in FY2025.","Gross margin improved to 66.2% from 62.8%, driven by higher-margin Emrosi and Qbrexza.","Adjusted EBITDA positive $2.9M ($0.12 per diluted share) vs $0.8M in prior year.","SG&A rose 10% to $44.4M due to Emrosi commercialization costs.","Accutane revenue declined $6.5M amid competitive pressures."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-034506","json":"https://secwatch.observer/filing/0001104659-26-034506.json","markdown":"https://secwatch.observer/filing/0001104659-26-034506.md","text":"https://secwatch.observer/filing/0001104659-26-034506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465926034506/0001104659-26-034506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465926034506/tm269707d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:04:15.936865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}